

08 Feb 2017 | News

# Number To Know...76,000,000

by

\$76m is the size of regenerative medicine specialist MiMedx's share purchase reprogram, which has just been expanded after its board decided it was "a favorable investment" for the company.

\$76m is the size of MiMedx's share repurchase program after its board of directors this month authorized for the amount to be expanded by an additional \$10m.

MiMedx specializes in regenerative biomaterials and bioimplants processed from human amniotic membrane. It has a number of products cleared for marketing by US FDA, including *EpiFix*, which is cleared for treating diabetic foot ulcers and chronic venous ulcers, and is in preclinical trial to assess its use in cardiovascular disease. It also has in development other products for orthopedic and cardiovascular indications. MiMedx said that in light of the prevailing market conditions, the company's available resources and other factors, the board believes the stock repurchases are a favorable investment for the company.

*Meddevicetracker* subscribers can access a profile of MiMedx, including data on its product portfolio, [here](#).

Not a subscriber? [Click here to request your free demo](#).